My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

16.66 +0.08 (+0.48%)

Streaming Delayed Price Updated: 12:20 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

March 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

March 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

March 19, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

January 15, 2024

Via Benzinga

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

December 25, 2023

Via Benzinga

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

March 19, 2024

From Centogene NV

Via GlobeNewswire

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

March 13, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Hot List: 3 AI Stocks Worth Buying on Weakness ↗

March 01, 2024

Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.

Via InvestorPlace

Topics Artificial Intelligence

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

February 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus ↗

February 12, 2024

Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.

Via Benzinga

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

February 12, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study ↗

February 09, 2024

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.

Via Benzinga

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

February 08, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? ↗

February 01, 2024

Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.

Via Benzinga

Takeda Announces Chief Financial Officer Succession

February 01, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

February 01, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 29, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 29, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 Stocks to Buy to Benefit From the Booming Sleep Industry ↗

January 23, 2024

It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.

Via InvestorPlace

Takeda Named Global Top Employer for Seventh Consecutive Year

January 18, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Time to buy these 3 healthcare companies that raised revenue guidance?

January 16, 2024

The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.

Via MarketBeat

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 16, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

One Ultra-Cheap High-Yield Dividend Stock to Buy ↗

December 22, 2023

Now may be a good time for dividend investors to consider loading up on this stock.

Via The Motley Fool

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

December 21, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

December 15, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.